tiprankstipranks
Advertisement
Advertisement
AC Immune reports Q1 EPS (15c), consensus (14c)
PremiumThe FlyAC Immune reports Q1 EPS (15c), consensus (14c)
2M ago
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
Premium
Company Announcements
AC Immune Triggers $12 Million Takeda Milestone as Final ABATE Cohort Starts in Alzheimer’s Trial
2M ago
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
Premium
Company Announcements
AC Immune Posts Q1 2026 Update, Extends Cash Runway and Advances Neurodegeneration Pipeline
2M ago
AC Immune’s PET tracer shows efficacy detecting brain pathologies
PremiumThe FlyAC Immune’s PET tracer shows efficacy detecting brain pathologies
3M ago
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating
Premium
Ratings
AC Immune: Advancing Neurology Pipeline and Imminent Alzheimer’s Vaccine Data Support Buy Rating
3M ago
AC Immune: Advancing Alzheimer’s and Parkinson’s Pipeline Catalysts Underpin Buy Rating and Favorable Risk‑Reward
Premium
Ratings
AC Immune: Advancing Alzheimer’s and Parkinson’s Pipeline Catalysts Underpin Buy Rating and Favorable Risk‑Reward
3M ago
AC Immune initiates Phase 1 trial of NLRP3 inhibitor
PremiumThe FlyAC Immune initiates Phase 1 trial of NLRP3 inhibitor
4M ago
AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027
Premium
Company Announcements
AC Immune Says Janssen Pauses Enrollment in Alzheimer’s Trial but Confirms Cash Runway to Q3 2027
4M ago
Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results
Premium
Ratings
Promising Advancements in Parkinson’s Treatment: AC Immune’s ACI-7104 Vaccine Shows Groundbreaking Results
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100